|Bid||170.00 x 800|
|Ask||224.40 x 800|
|Day's Range||193.51 - 207.50|
|52 Week Range||94.02 - 287.79|
|Beta (3Y Monthly)||1.63|
|PE Ratio (TTM)||135.77|
|Earnings Date||Nov 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||264.80|
Short interest is low for INGN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $3.24 billion over the last one-month into ETFs that hold INGN are not among the highest of the last year and have been slowing.
Zacks.com featured highlights include: Callaway Golf, Herbalife, IAC/InterActiveCorp, Inogen and Salesforce.com
Inogen, Inc. , a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release third quarter 2018 financial results after market close on Tuesday, November 6, 2018.
Inogen (INGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Inogen Inc (NASDAQ:INGN), with a market cap of US$5.1b, often get neglected Read More...
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
NEW YORK , Sept. 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Rollins Inc. (NYSE: ROL) ...
A leading player in the oxygen therapy market, Inogen (INGN) reported a rise in its stock of 121.6%, from $119.17 on January 2, 2018, to $263.85 on September 7, 2018. Inogen is focused on investing in its operations and marketing and sales efforts to increase the adoption of its portable oxygen concentrations globally. In Q2 2018, Inogen reported revenues of $97.2 million, a YoY (year-over-year) rise of 51.7%.
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that after nearly 15 years of dedicated support to Inogen’s growth and success, Matt Scribner, Inogen’s Executive Vice President of Operations, plans to leave Inogen effective January 2nd, 2019. The Company has appointed Bart Sanford as Inogen’s Executive Vice President of Operations effective September 17th, 2018. “Matt has been a part of the Company’s success and I want to thank him for his many contributions to Inogen over the years and wish him the best in his future endeavors,” said Chief Executive Officer, Scott Wilkinson.
Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Inogen, Inc. , a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 16h Annual Morgan Stanley Global Healthcare Conference in New York City.
Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.